التفاصيل البيبلوغرافية
| العنوان: |
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. |
| المؤلفون: |
Wakatsuki, Takeru, Yamamoto, Noriko, Sano, Takeshi, Chin, Keisho, Kawachi, Hiroshi, Takahari, Daisuke, Ogura, Mariko, Ichimura, Takashi, Nakayama, Izuma, Osumi, Hiroki, Matsushima, Tomohiro, Suenaga, Mitsukuni, Shinozaki, Eiji, Hiki, Naoki, Ishikawa, Yuichi, Yamaguchi, Kensei |
| المصدر: |
Journal of Gastroenterology; Nov2018, Vol. 53 Issue 11, p1186-1195, 10p, 1 Color Photograph, 4 Charts, 2 Graphs |
| مصطلحات موضوعية: |
HER2 gene, TRASTUZUMAB, BREAST cancer, ANTINEOPLASTIC agents, CANCER |
| مستخلص: |
Background: There is growing interest in the clinical significance of intratumoral HER2 heterogeneity. Its prognostic and predictive impacts on trastuzumab efficacy were demonstrated in breast cancer. However, its clinical significance in gastric cancer is still unclear.Methods: Twenty-eight HER2-positive gastric cancer patients who had gastrectomy prior to trastuzumab-based chemotherapy were consecutively enrolled. Intratumoral HER heterogeneity was evaluated using whole-tissue sections by immunohistochemistry. When all tumor cells overexpressed HER2 protein, the tumor was defined as homogeneously HER2 (Homo-HER2)-positive group. The others were defined as heterogeneously HER2 (Hetero-HER2)-positive group.Results: There was no significant difference in clinicopathological features between the two groups. The median progression-free survival (PFS) and overall survival (OS) in the Homo-HER2-positive group were significantly longer than those in the Hetero-HER2-positive group (PFS; 20.0 months [95% CI 17.8-22.2] vs. 6.0 months [95% CI 2.3-9.7]; HR 0.11; 95% CI 0.03-0.41; p < 0.001, OS; not reached vs. 14.0 months [95% CI 11.9-16.1]; HR 0.18; 95% CI 0.06-0.61; p = 0.003). In the multivariate analysis, these associations remained significant both in PFS (HR 0.12; 95% CI 0.03-0.46, p = 0.002) and OS (HR 0.21; 95% CI 0.06-0.72, p = 0.013). With respect to response rate, no statistical difference was found between two groups. However, deeper tumor shrinkage was obtained in the Homo-HER2-positive group compared with the Hetero-HER2-positive group (p = 0.046).Conclusions: Intratumoral HER2 heterogeneity may have robust clinical impact on trastuzumab efficacy in patients with HER2-positive gastric cancer. These findings should be validated by larger independent cohorts and further molecular correlative analyses are warranted. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Gastroenterology is the property of Springer Nature and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
